



FOR IMMEDIATE RELEASE

Affimed Appoints Dr. Leila Alland as Chief Medical Officer

Heidelberg, Germany, March 19, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the appointment of Dr. Leila Alland to the position of Chief Medical Officer (CMO), effective March 26, 2018. As CMO, Dr. Alland will be responsible for the clinical strategy and execution of Affimed's first-in-class NK and T cell engager programs through early and late stage clinical trials. Dr. Alland brings to the Company over 20 years of experience in industry and academic research with a strong track record of successful oncology and hematology drug development.

"I am pleased to announce the appointment of Dr. Alland as our new Chief Medical Officer as she brings with her a wealth of expertise in immuno-oncology drug development including PD-1- and EGFR-targeting agents," said Dr. Adi Hoess, CEO of Affimed. "With Dr. Alland leading our strategy and execution in the clinic, we look forward to advancing our robust pipeline of both mono- and combination therapeutics through clinical development to regulatory approval."

Dr. Alland has broad experience as a clinical leader developing both large and small molecule oncology products for solid and hematological malignancies, including Opdivo[®], Tagrisso[®], and Tassigna[®]. Dr. Alland most recently served as CMO of Tarveda Therapeutics, developing clinical candidates for solid tumors. Prior to that, she was Vice President and Head of Oncology Early Clinical Development at AstraZeneca where she led Phase 1 and Phase 2 clinical development of oncology and immuno-oncology programs including a Phase 2 registration study that contributed to the accelerated approval of Tagrisso[®]. Previously, Dr. Alland served at Bristol-Myers Squibb as clinical head for multiple early phase oncology programs including immuno-oncology antibody therapeutics, and at Novartis where she led the clinical development program for Tassigna[®]. Dr. Alland is also an experienced pediatric hematologist/oncologist and accomplished scientist, having served on the faculty at Albert Einstein College of Medicine, New York City, where she was awarded the prestigious James S. McDonnell Foundation Scholar Award for research.

“Affimed’s novel tetravalent bispecific antibodies for immune cell engagement offer a unique approach to accelerate the trajectory of the immuno-oncology field and achieve significant benefit for patients,” said Dr. Leila Alland. “I am excited to be joining the accomplished team at Affimed and look forward to advancing the differentiated pipeline of NK and T cell engagers for patients with Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia and other malignancies.”

Dr. Alland completed her fellowship in pediatric hematology and oncology at Memorial Sloan Kettering Cancer Center, NY and her internship and residency at The Children’s Hospital of Philadelphia, PA. She received her B.A. from the University of Pennsylvania and her M.D. from New York University School of Medicine.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the safety and efficacy of our product candidates, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates our intellectual property position, our collaboration activities, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Contact:

Anca Alexandru, Head of Communications, EU IR

Phone: +49 6221 64793341

E-Mail: a.alexandru@affimed.com, IR@affimed.com